Kak..massive potential ?... so you see what Big Pharmas see ?
A good starting point is Novartis valuing Gamida Cell (currently conducting two Phase I/II trials) at $233m (15% for $35m).
How would you value 12 applications in P2 ( 3currently in Phase III) ?
...there will come a point where it so compelling that it will be clear to all that MSB is undervalued.
DYOR.
Novartis stem cell action, page-16
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
-0.050(3.31%) |
Mkt cap ! $1.681B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.50 | $1.45 | $6.532M | 4.455M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 12171 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 64352 | 19 |
View Market Depth
| Last trade - 14.43pm 08/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |